Core A: Administration The Administrative Core A (Admin Core) provides the administrative framework to support the four Projects and the other Core of this PPG. Its main focus is to allow the PPG investigators to dedicate their efforts on scientific advances to fulfill the goals of this PPG. The Core is led by Antoni Ribas, M.D. with the Core Co- lnvestigator David Gjertson, Ph.D., the senior PPG biostatistician. With this resubmission Core A incorporates a new service, bioinformatics support, which is a common need for the four Projects to allow adequate interpretation of high throughput data and the ability to use advanced algorithms for its analysis This will be provided by Stan Nelson, M.D. and Tom Graeber, Ph.D. It is supported by a staff biostatistician, a regulatory coordinator, an administrative and a fund manager, and a clinical trials coordinator and data manager. The Core has two specific Aims.
Aim 1 is focused on fostering the scientific aspects of the PPG providing oversight of meeting the milestones and objectives for each Project and Core. This will be facilitated by a series of in-process and formal evaluation meetings with the oversight of the Internal Advisory Board (lAB) made up by four senior Investigators at UCLA and Caltech, James Economou, M.D., Ph.D., James Heath, Ph.D. (Caltech), Owen Witte, M.D., and Hong Wu, Ph.D. This oversight and scientific support is extended by the engagement of three External Expert Consultants (EEC). Boris Bastian, M.D., Ph.D. (UCSF), Charles Sawyers, M.D. (MSKCC) and Cassian Yee (Fred Hutch).
Aim 2 is focused on providing the appropriate administrative and fiscal support for the daily activities within PPG. This includes administrative and coordination support, facilitating data and resource sharing plans, clinical trial and biospecimen regulatory, study coordination and data management.

Public Health Relevance

The Admin Core will support all Projects and Cores to allow them to focus the efforts on the proposed scientific plans. As such, it is an integral part of the PPG scientific goals and provides Its relevance for the proposed patient-oriented research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA168585-02
Application #
8686788
Study Section
Special Emphasis Panel (ZCA1-RPRB-C)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
2
Fiscal Year
2014
Total Cost
$245,187
Indirect Cost
$85,665
Name
University of California Los Angeles
Department
Type
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Homet Moreno, Blanca; Zaretsky, Jesse M; Garcia-Diaz, Angel et al. (2016) Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells. Cancer Immunol Res 4:845-857
Escuin-Ordinas, Helena; Li, Shuoran; Xie, Michael W et al. (2016) Cutaneous wound healing through paradoxical MAPK activation by BRAF inhibitors. Nat Commun 7:12348
Ribas, Antoni; Shin, Daniel Sanghoon; Zaretsky, Jesse et al. (2016) PD-1 Blockade Expands Intratumoral Memory T Cells. Cancer Immunol Res 4:194-203
Hong, Candice Sun; Graham, Nicholas A; Gu, Wen et al. (2016) MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4. Cell Rep 14:1590-601
Robert, Lidia; Ribas, Antoni; Hu-Lieskovan, Siwen (2016) Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2? Semin Immunol 28:73-80
Shin, Daniel Sanghoon; Zaretsky, Jesse M; Escuin-Ordinas, Helena et al. (2016) Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. Cancer Discov :
Tavaré, Richard; Escuin-Ordinas, Helena; Mok, Stephen et al. (2016) An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy. Cancer Res 76:73-82
Titz, Bjoern; Lomova, Anastasia; Le, Allison et al. (2016) JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma. Cell Discov 2:16028
Ribas, Antoni; Hu-Lieskovan, Siwen (2016) What does PD-L1 positive or negative mean? J Exp Med 213:2835-2840
Atefi, Mohammad; Titz, Bjoern; Tsoi, Jennifer et al. (2016) CRAF R391W is a melanoma driver oncogene. Sci Rep 6:27454

Showing the most recent 10 out of 51 publications